Markets:

Overview

News

Currencies

International

Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

16.94 -0.41 (-2.36%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors

January 09, 2023

From NeuroPace, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 02, 2023

Via Benzinga

NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022

From NeuroPace, Inc.

Via GlobeNewswire

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

November 30, 2022

From NeuroPace, Inc.

Via Business Wire

NeuroPace: Q2 Earnings Insights ↗

August 11, 2022

NeuroPace (NASDAQ:NPCE) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

$10 Million Bet On Canoo? Check Out These 3 Stocks Under $3 Insiders Are Buying ↗

November 25, 2022

The Nasdaq Composite closed higher by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 24, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 14, 2022

Monday saw 33 companies set new 52-week lows.

Via Benzinga

NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update

November 08, 2022

From NeuroPace, Inc.

Via GlobeNewswire

Expert Ratings For NeuroPace ↗

April 06, 2022

Analysts have provided the following ratings for NeuroPace (NASDAQ:NPCE) within the last quarter:

Via Benzinga

Bear Of The Day: NeuroPace (NPCE) ↗

March 21, 2022

NeuroPace is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy.

Via Talk Markets

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference

November 04, 2022

From NeuroPace, Inc.

Via GlobeNewswire

NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

October 25, 2022

From NeuroPace, Inc.

Via GlobeNewswire

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

October 11, 2022

From NeuroPace, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 25, 2022

On Tuesday, 120 companies set new 52-week lows.

Via Benzinga

NeuroPace's Return On Capital Employed Insights ↗

September 07, 2022

NeuroPace (NASDAQ:NPCE) brought in sales totaling $10.20 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.72%, resulting in a loss of $12.69 million.

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

5 Analysts Have This to Say About NeuroPace ↗

May 13, 2022

Over the past 3 months, 5 analysts have published their opinion on NeuroPace (NASDAQ:NPCE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Recap: NeuroPace Q1 Earnings ↗

May 12, 2022

NeuroPace (NASDAQ:NPCE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NeuroPace missed estimated earnings...

Via Benzinga

NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents

May 04, 2022

From NeuroPace, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

February 02, 2022

During Wednesday's session, 18 companies made new 52-week lows. Noteable 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) is the largest company in terms of market...

Via Benzinga

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗

January 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 07, 2022

On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (...

Via Benzinga

58 Biggest Movers From Yesterday ↗

December 14, 2021

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...

Via Benzinga

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.